Drug intelligence / Profile preview

Aom0187

Development stage: Preclinical
Lead developer: Hangzhou Adamerck Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

Aom0187 is a new chemical entity under development by Aomo Pharma for the treatment of dry eye disease. Preclinical data indicate that Aom0187 can significantly improve symptoms of dry eye in animal models and demonstrates good therapeutic effects. As of early 2024, Aom0187 is in preclinical evaluation and expected to enter clinical trials soon. The specific mechanism of action has not been disclosed, but it is positioned as an innovative therapy for ophthalmic conditions, particularly targeting dry eye disease.

Beyond the preview

Go deeper on Aom0187.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aom0187.

Explore the full profile